1268684-03-2

Upstream product

• 70-23-5 ethyl Bromopyruvate 
• 1268684-05-4 C₁₃H₁₅ClFIN₂ 
• 1268684-06-5 3-chloro-2-fluoro-6-iodoaniline 
• 2106-04-9 3-chloro-2-fluoroaniline 

Downstream Products

• 1268680-63-2 1-(6-carboxymethyl-3-chloro-2-fluoro-phenyl)-5-(3-chloro-4-fluoro-phenyl)-2-cyclohexyl-1H-imidazole-4-carboxylic acid ethyl ester 
• 1268684-01-0 C₂₀H₂₂ClFN₂O₄ 
• 1268684-00-9 C₂₀H₂₁BrClFN₂O₄ 
• 1268680-66-5 1-(6-tert-butoxycarbonylmethyl-3-chloro-2-fluoro-phenyl)-5-(3-chloro-4-fluoro-phenyl)-2-cyclohexyl-1H-imidazole-4-carboxylic acid ethyl ester 
• 1268680-69-8 1-(6-tert-butoxycarbonylmethyl-3-chloro-2-fluoro-phenyl)-5-(3-chloro-4-fluoro-phenyl)-2-cyclohexyl-1H-imidazole-4-carboxylic acid 
• 1268680-89-2 C₂₈H₃₀Cl₂F₂N₄O₃ 
• 1268684-02-1 C₂₃H₂₈ClFN₂O₂Si 

Relevant academic research and scientific papers

Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction

Capitalizing on crystal structure information obtained from a previous effort in the search for non peptide inhibitors of the p53-MDM2 interaction, we have discovered another new class of compounds able to disrupt this protein-protein interaction, an important target in oncology drug research. The new inhibitors, based on a tetra-substituted imidazole scaffold, have been optimized to low nanomolar potency in a biochemical assay following a structure-guided approach. An appropriate strategy has allowed us to translate the high biochemical potency in significant anti-proliferative activity on a p53-dependent MDM2 amplified cell line.